Sanofi & Regeneron’s Dupixent receives US FDA approval to treat patients with bullous pemphigoid: Paris Saturday, June 21, 2025, 12:00 Hrs [IST] The US Food and Drug Administrat ...

In July, the European Commission became the first regulator worldwide to approve Sanofi and Regeneron's big-selling IL-4 and IL-13 inhibitor Dupixent (dupilumab) as a treatment for the lung ...

Examples here are Sanofi/Regeneron’s Dupixent, which is indicated in six settings, and AbbVie’s Skyrizi. The list of fastest-growing drugs in 2025 is dominated by the incretin-based therapies ...